Top in allergy/asthma: Tezspire reduces exacerbations; remibrutinib effective for hives

Tezspire reduced asthma exacerbations across all seasons, regardless of sensitivities to perennial and seasonal aeroallergens, a recent study showed.

Researchers said the findings demonstrate the efficacy of Tezspire (tezepelumab; Amgen, AstraZeneca) for a broad population of patients. It was the top story in allergy/asthma last week.

Another top story was about how a year-long treatment with remibrutinib improved symptoms for patients with chronic spontaneous urticaria.

Read these and more top stories in allergy/asthma below:

Tezepelumab reduces asthma exacerbations season by season

Tezepelumab reduced exacerbations among patients with severe, uncontrolled asthma across all seasons regardless of their specific seasonal and perennial allergies, according to a study published in Annals of Allergy, Asthma & Immunology. Read more.

Remibrutinib safe, effective for chronic spontaneous urticaria over 52 weeks

Patients with chronic spontaneous urticaria showed rapid symptom improvement with a favorable safety profile over 52 weeks of treatment with remibrutinib, data show. Read more.

Comorbidities add treatment burdens to atopic dermatitis

Researchers reported that patients with atopic dermatitis with comorbidities face additional treatment burdens and barriers. Read more.

About one in 260 people in the United States has a coconut allergy

Approximately one in 260 people in the United States reported symptoms consistent with an IgE-mediated coconut allergy, according to a study published in Annals of Allergy, Asthma & Immunology. Read more.

Mast cells, wellness, biologics take spotlight at ACAAI Annual Scientific Meeting

Providers gathered in Anaheim under the banner of “Embracing the Evolution of Patient Care” for the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting. Read more.